STING1 and neoplasm: In that study, they used STING agonists to promote the expansion of interleukin (IL)-35-secreting B (IL-35+ B) cells for the production of IL-35 and IL-10 and found that the intratumoral levels of these anti-inflammatory cytokines had a negative relationship with NK cell infiltration and a positive relationship with tumor weight.